open access
Molecular diagnosis in type I epithelial ovarian cancer
- Katedra i Klinika Połoznictwa, Chorób Kobiecych i Ginekologii Onkologicznej Collegium Medicum UMK w Bydgoszczy, ul. Ujejskiego 75, 85-168 Bydgoszcz, Poland
open access
Abstract
Abstract
Keywords
low grade ovarian cancer, type 1 ovarian cancer, borderline ovarian tumors, KRAS mutation, BRAF mutation, NRAS mutation
Title
Molecular diagnosis in type I epithelial ovarian cancer
Journal
Issue
Article type
Review paper
Pages
692-697
Published online
2017-12-29
Page views
3140
Article views/downloads
2710
DOI
Pubmed
Bibliographic record
Ginekol Pol 2017;88(12):692-697.
Keywords
low grade ovarian cancer
type 1 ovarian cancer
borderline ovarian tumors
KRAS mutation
BRAF mutation
NRAS mutation
Authors
Paweł Sadłecki
Małgorzata Walentowicz-Sadłecka
Marek Grabiec
- Gąsiorowska E, Michalak M, Warchoł W, et al. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Ginekol Pol. 2015; 86(2): 88–93.
- Shih IM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5): 1511–1518.
- Shaw PA, McLaughlin JR, Zweemer RP, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol. 2002; 21(4): 407–411.
- Skead G, Govender D. Gene of the month: MET. J Clin Pathol. 2015; 68(6): 405–409.
- Huang J, Zhang L, Greshock J, et al. Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer. 2011; 50(8): 606–618.
- Olson JM, Hallahan AR. p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med. 2004; 10(3): 125–129.
- Hsu CY, Bristow R, Cha MS, et al. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Clin Cancer Res. 2004; 10(19): 6432–6436.
- Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016; 140(3): 457–462.
- Ramalingam P. Morphologic, Immunophenotypic, and Molecular Features of Epithelial Ovarian Cancer. Oncology (Williston Park). 2016; 30(2): 166–176.
- Malpica A, Deavers MT. Ovarian low-grade serous carcinoma involving the cervix mimicking a cervical primary. Int J Gynecol Pathol. 2011; 30(6): 613–619.
- Phillips V, Kelly P, McCluggage WG. Increased p16 expression in high-grade serous and undifferentiated carcinoma compared with other morphologic types of ovarian carcinoma. Int J Gynecol Pathol. 2009; 28(2): 179–186.
- Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005; 29(2): 218–224.
- Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013; 119(3): 548–554.
- Zeppernick F, Ardighieri L, Hannibal CG, et al. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors. Am J Surg Pathol. 2014; 38(12): 1603–1611.
- Singer G, Oldt R, Cohen Y, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst. 2003; 95(6): 484–486.
- Houghton O, Connolly LE, McCluggage WG. Morules in endometrioid proliferations of the uterus and ovary consistently express the intestinal transcription factor CDX2. Histopathology. 2008; 53(2): 156–165.
- Yemelyanova A, Ji H, Shih IM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009; 33(10): 1504–1514.
- Soliman PT, Broaddus RR, Schmeler KM, et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005; 23(36): 9344–9350.
- Catasús L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004; 35(11): 1360–1368.
- Silva EG, Deavers MT, Malpica A. Patterns of low-grade serous carcinoma with emphasis on the nonepithelial-lined spaces pattern of invasion and the disorganized orphan papillae. Int J Gynecol Pathol. 2010; 29(6): 507–512.
- Taraif SH, Deavers MT, Malpica A, et al. The significance of neuroendocrine expression in undifferentiated carcinoma of the endometrium. Int J Gynecol Pathol. 2009; 28(2): 142–147.
- Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011; 42(7): 918–931.
- Ryland G, Hunter S, Doyle M, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015; 7(1).
- Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003; 27(7): 985–993.
- Alexandre J, Ray-Coquard I, Selle F, et al. GINECO. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010; 21(12): 2377–2381.
- Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013; 229(1): 111–120.
- Grisham RN, Iyer G, Garg K, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer. 2013; 119(3): 548–554.
- Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003; 90(2): 378–381.
- Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013; 95(2): 235–241.
- Chan JK, Teoh D, Hu JM, et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol. 2008; 109(3): 370–376.
- Sugiyama T, Kamura T, Kigawa J, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000; 88(11): 2584–2589.
- Wu RC, Ayhan A, Maeda D, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. J Pathol. 2014; 232(4): 473–481.
- Köbel M, Reuss A, du Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010; 222(2): 191–198.
- Kuo KT, Mao TL, Chen Xu, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009; 174(5): 1597–1601.
- Willner J, Wurz K, Allison KH, et al. Alternate molecular genetic pathways in ovarian carcinomas of common histological types. Hum Pathol. 2007; 38(4): 607–613.
- Jones S, Wang TL, Shih IM, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001): 228–231.
- Auner V, Kriegshäuser G, Tong D, et al. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer. 2009; 9: 111.
- Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013; 95(2): 235–241.
- Despierre E, Yesilyurt BT, Lambrechts S, et al. EORTC GCG and EORTC GCG Translational Research Group. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer. 2014; 24(3): 468–477.
- Zannoni GF, Improta G, Chiarello G, et al. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch. 2014; 465(2): 193–198.
- Anderson SM. Laboratory methods for KRAS mutation analysis. Expert Rev Mol Diagn. 2011; 11(6): 635–642.
- Haley L, Tseng LH, Zheng G, et al. Performance characteristics of next-generation sequencing in clinical mutation detection of colorectal cancers. Mod Pathol. 2015; 28(10): 1390–1399.
- Janku F, Huang HJ, Claes B, et al. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015; 6(29): 26886–26894.
- Sadlecki P, Walentowicz P, Bodnar M, et al. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Tumour Biol. 2017; 39(5): 1010428317706230.